Allogene Therapeutics Analyst Ratings
Piper Sandler Initiates Coverage On Allogene Therapeutics With Overweight Rating, Announces Price Target of $11
Allogene Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Savara (SVRA), Allogene Therapeutics (ALLO)
Allogene Therapeutics Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), Allogene Therapeutics (ALLO)
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Generation Bio (GBIO)
Allogene Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)
Allogene Therapeutics Analyst Ratings
Allogene Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)
Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO) and Pliant Therapeutics (PLRX)
Allogene Therapeutics Analyst Ratings
Allogene Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR) and Allogene Therapeutics (ALLO)
Allogene Therapeutics Analyst Ratings
Allogene Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Allogene Therapeutics, Lowers Price Target to $12
Allogene Therapeutics Analyst Ratings